Oxford BioMedica set to earn $100 million in deal with Sanofi takeover target
UK gene cell therapy designer Oxford BioMedica’s (LSE: OXB) shares jumped as much as 11.2% to 12.30 pence this morning after announcing a $100 million collaboration and licence agreement with US hemophilia specialist Bioverativ (Nasdaq: BIVV), which last month agreed to be acquired by French pharma major Sanofi (Euronext: SAN) in a $11.6 billion deal.
The agreement includes a licence to use OXB's LentiVector Enabled technology and access to its industrial-scale manufacturing technology.
Under the terms of the agreement, Oxford BioMedica will receive a $5 million upfront from Bioverativ. Oxford BioMedica is also eligible for various milestone payments, potentially worth in excess of $100 million, and undisclosed royalties on net sales of Bioverativ's lentiviral vector hemophilia products.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze